40th ASCO 2004; 23: 627 (abstract 7055).\r[27] De Groot V, Beckerman H, Lankhorst GJ et al. How to measure\rcomorbidity: a critical review of available methods. J Clin Epidemiol 2003;\r56: 221-229.\r[28] Gov indan R, Garfield DH. Treatment approaches in patients with\radvanced non-small cell lung cancer and poor performance status. Semin\rOncol 2004; 31 (Suppl. 11): 27-31.\r[29] Deppermann KM. Influence of age and comorbidities on the\rchemotherapeutic management of lung cancer. Lung Cancer 2001; 33 (Suppl.\r1): SU5-S120.\r[30 Langer C, Barsevick A, Bruner D et al. Correlation of quality of life\r(QOL) with survival, treatment response and anemia in patients advanced\rnon-small cell lung cancer (NSCLC) treated with carboplatin and\rpaclitaxel. Lung Cancer 1997; 18: 23 (abstract).\r65
全文预览
